Table 1.
Characteristic | All patients n (or median) | % (or min.–max.) | Without TDR (WHO SDRM criteria) n (or median) | % (or min.–max.) | With TDR (WHO SDRM criteria) n (or median) | % (or min.–max.) | OR [95% CI] | p-value |
---|---|---|---|---|---|---|---|---|
Total | 103 | 100.0% | 95 | 100.0% | 8 | 100.0% | — | — |
Men | 47 | 46.1% | 43 | 45.7% | 4 | 50.0% | 1.19 [0.28, 5.03] | 0.82 |
Age at time of test (years) | 38.6 | 17.8–62.5 | 38.9 | 17.8–62.5 | 35.4 | 24.0–55.7 | — | 0.25 |
Time since diagnosis (years) | 3.0 | 0–19.0 | 3.5 | 0–19.0 | 1.0 | 0–7.0 | — | 0.08 |
HIV risk factor | ||||||||
Heterosexual sex | 82 | 82.8% | 76 | 83.5% | 6 | 75.0% | 1.0 | — |
MSM | 10 | 10.1% | 9 | 9.9% | 1 | 12.5% | 1.41 [0.15, 13.05] | 0.76 |
Other/multiple/unknown | 7 | 7.1% | 6 | 6.6% | 1 | 12.5% | 2.11 [0.22, 20.52] | 0.52 |
Received sdNVP for PMTCT (females only) | 7 | 13.7% | 7 | 13.7% | 0 | 0% | — | 1.00 |
HIV status of past/current partners | ||||||||
Negative | 13 | 13.0% | 12 | 13.0% | 1 | 12.5% | 1.0 | — |
Positive | 53 | 53.0% | 48 | 52.2% | 5 | 62.5% | 1.25 [0.13, 11.72] | 0.85 |
Don't know | 34 | 34.0% | 32 | 34.8% | 2 | 25.0% | 0.75 [0.06, 9.05] | 0.82 |
Prior/active commercial sex work | 15 | 15.0% | 13 | 14.1% | 2 | 25.0% | 2.03 [0.37, 11.14] | 0.34 |
Number of lifetime partners | 4 | 0–300 | 4 | 0–300 | 3.5 | 0–33 | — | 0.88 |
Prior travel outside the DR | 10 | 9.9% | 9 | 9.7% | 1 | 12.5% | 1.33 [0.15, 12.10] | 0.80 |
Baseline1 laboratory studies | ||||||||
CD4+ count (cells/μl) | 216 | 5–724 | 218 | 5–724 | 185 | 101–236 | — | 0.28 |
HIV-1 plasma RNA (copies/ml) | 59,604 | 320–2,836,323 | 61,919 | 320–2,836,323 | 23,226 | 4,618–102,185 | — | 0.25 |
Baseline CD4 and HIV-1 plasma RNA level values were defined as those measured from 1 year prior to the genotype date and for up to 7 days afterward (provided ART had not yet been initiated).
sdNVP, single-dose nevirapine; PMTCT, prevention of mother-to-child transmission; MSM, men who have sex with men; DR, Dominican Republic.